Jessica Anderson
Family · Plymouth, MANPI 1104220805
Payments from drug & device makers
Across 59 payments — averaging $25.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Antares Pharma, Inc.$160
- Sumitomo Pharma America, Inc.$157
- Endo USA, Inc.$150
- Immunitybio, Inc.$106
- Johnson & Johnson$98
- Convatec Inc.$85
- plus $739 from 17 others
What the payments were for
- Food & beverage$1,496100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Antares Pharma, Inc. | 6 | $160 |
| Sumitomo Pharma America, Inc. | 6 | $157 |
| Endo USA, Inc. | 6 | $150 |
| Immunitybio, Inc. | 5 | $106 |
| Johnson & Johnson | 3 | $98 |
| Convatec Inc. | 2 | $85 |
| Ferring Pharmaceuticals Inc. | 3 | $75 |
| Coloplast | 3 | $71 |
| Tolmar, Inc. | 3 | $71 |
| Astellas Pharma US Inc | 3 | $70 |
| Telix Pharmaceuticals | 3 | $55 |
| Boston Scientific | 2 | $51 |
| Endo Pharmaceuticals Inc. | 2 | $50 |
| Accord Healthcare, Inc. | 2 | $49 |
| ABC Home Medical Supply, Inc. | 2 | $49 |
| Urogen Pharma, Inc. | 1 | $38 |
| 180 Medical, Inc. | 1 | $28 |
| Bioprotect Medical, Inc. | 1 | $27 |
| Merck | 1 | $27 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $23 |
| Dendreon Pharmaceuticals LLC | 1 | $22 |
| BD | 1 | $17 |
| Teleflex LLC | 1 | $16 |
How this compares
$1,496 in reported general payments places this provider in the 85th percentile of 2,320 family providers in Massachusetts.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 21 | $15,837 |
| MyrbetriqMirabegron | 15 | $8,844 |
| Methenamine Hippurate | 32 | $1,672 |
| Estradiol | 18 | $1,322 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 60 | $555 |
| Tamsulosin Hcl | 55 | $509 |
| Cefdinir | 46 | $467 |
| Cephalexin | 90 | $359 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 12 | $347 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 15 | $221 |
| Finasteride | 21 | $158 |
| Ciprofloxacin Hcl | 46 | $154 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 27 | $78 |
| Amoxicillin | 14 | $36 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $157 | $15,83721 claims |
| Astellas Pharma US IncMyrbetriq | $70 | $8,84415 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,320 family providers in Massachusetts.
Other family in Plymouth
- Brittany WalshPlymouth$8K
- Paul GouldLakeville$343K
- Brittany MurrayBoston$141K
- Courtney NixonAmherst$81K
- Elizabeth WalshBrighton$80K
- Jennifer FlemingLawrence$80K
- Naomi AmudalaBoston$79K
- Geoffrey WhitleyCharlestown$66K
- Katherine O'BrienWinthrop$58K
- Kristy SmithActon$57K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.